CL2015000890A1 - Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras. - Google Patents
Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras.Info
- Publication number
- CL2015000890A1 CL2015000890A1 CL2015000890A CL2015000890A CL2015000890A1 CL 2015000890 A1 CL2015000890 A1 CL 2015000890A1 CL 2015000890 A CL2015000890 A CL 2015000890A CL 2015000890 A CL2015000890 A CL 2015000890A CL 2015000890 A1 CL2015000890 A1 CL 2015000890A1
- Authority
- CL
- Chile
- Prior art keywords
- ethynyl
- anxiety
- parkinson
- modulators
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12188943 | 2012-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015000890A1 true CL2015000890A1 (es) | 2015-08-07 |
Family
ID=47049068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015000890A CL2015000890A1 (es) | 2012-10-18 | 2015-04-09 | Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras. |
Country Status (26)
Country | Link |
---|---|
US (1) | US9359301B2 (es) |
EP (1) | EP2909178B1 (es) |
JP (1) | JP6263542B2 (es) |
KR (1) | KR20150070102A (es) |
CN (1) | CN104603110B (es) |
AR (1) | AR093029A1 (es) |
AU (1) | AU2013331782B2 (es) |
BR (1) | BR112015002320A2 (es) |
CA (1) | CA2879489A1 (es) |
CL (1) | CL2015000890A1 (es) |
CR (1) | CR20150158A (es) |
EA (1) | EA026941B1 (es) |
ES (1) | ES2599507T3 (es) |
HK (1) | HK1206715A1 (es) |
IL (1) | IL237217A (es) |
MA (1) | MA38010B1 (es) |
MX (1) | MX2015002823A (es) |
MY (1) | MY171517A (es) |
NZ (1) | NZ703537A (es) |
PE (1) | PE20150733A1 (es) |
PH (1) | PH12015500346A1 (es) |
SG (1) | SG11201500729SA (es) |
TW (1) | TWI504593B (es) |
UA (1) | UA114008C2 (es) |
WO (1) | WO2014060384A1 (es) |
ZA (1) | ZA201500343B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102035048B1 (ko) * | 2015-06-03 | 2019-10-22 | 에프. 호프만-라 로슈 아게 | 에틴일 유도체 |
LT3322701T (lt) | 2015-07-15 | 2019-07-10 | F. Hoffmann-La Roche Ag | Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai |
EP3436009B1 (en) | 2016-03-30 | 2024-03-06 | Sinntaxis AB | Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages. |
DK3484889T3 (da) | 2016-07-18 | 2020-10-26 | Hoffmann La Roche | Ethynylderivater |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
US7531529B2 (en) * | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
US8853392B2 (en) * | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
US20100273772A1 (en) * | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) |
US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
US8772300B2 (en) * | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
US8957213B2 (en) * | 2011-04-26 | 2015-02-17 | Hoffman-La Roche Inc. | Ethynyl compounds |
WO2013049255A1 (en) * | 2011-09-26 | 2013-04-04 | Vanderbilt University | Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors |
UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
DK2875000T3 (en) * | 2012-07-17 | 2016-10-24 | Hoffmann La Roche | ARYLETHYNYL DERIVATIVES |
UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
DK2900659T3 (en) * | 2012-09-27 | 2016-10-03 | Hoffmann La Roche | ARYLETHYNYL DERIVATIVES |
AU2013333988B2 (en) * | 2012-10-18 | 2017-03-09 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mGluR5 receptor activity |
CA2882484A1 (en) * | 2012-10-18 | 2014-04-24 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mglur5 receptor activity |
-
2013
- 2013-10-15 PE PE2015000287A patent/PE20150733A1/es not_active Application Discontinuation
- 2013-10-15 EP EP13776507.9A patent/EP2909178B1/en active Active
- 2013-10-15 WO PCT/EP2013/071476 patent/WO2014060384A1/en active Application Filing
- 2013-10-15 EA EA201590676A patent/EA026941B1/ru not_active IP Right Cessation
- 2013-10-15 CA CA2879489A patent/CA2879489A1/en not_active Abandoned
- 2013-10-15 ES ES13776507.9T patent/ES2599507T3/es active Active
- 2013-10-15 MY MYPI2015000250A patent/MY171517A/en unknown
- 2013-10-15 BR BR112015002320A patent/BR112015002320A2/pt not_active Application Discontinuation
- 2013-10-15 KR KR1020157006701A patent/KR20150070102A/ko active IP Right Grant
- 2013-10-15 AU AU2013331782A patent/AU2013331782B2/en not_active Ceased
- 2013-10-15 UA UAA201504679A patent/UA114008C2/uk unknown
- 2013-10-15 CN CN201380046124.7A patent/CN104603110B/zh active Active
- 2013-10-15 MX MX2015002823A patent/MX2015002823A/es unknown
- 2013-10-15 NZ NZ703537A patent/NZ703537A/en not_active IP Right Cessation
- 2013-10-15 JP JP2015537217A patent/JP6263542B2/ja active Active
- 2013-10-15 SG SG11201500729SA patent/SG11201500729SA/en unknown
- 2013-10-16 AR ARP130103749A patent/AR093029A1/es unknown
- 2013-10-17 TW TW102137559A patent/TWI504593B/zh not_active IP Right Cessation
-
2015
- 2015-01-16 ZA ZA2015/00343A patent/ZA201500343B/en unknown
- 2015-02-12 IL IL237217A patent/IL237217A/en not_active IP Right Cessation
- 2015-02-17 PH PH12015500346A patent/PH12015500346A1/en unknown
- 2015-03-20 CR CR20150158A patent/CR20150158A/es unknown
- 2015-04-09 CL CL2015000890A patent/CL2015000890A1/es unknown
- 2015-04-17 MA MA38010A patent/MA38010B1/fr unknown
- 2015-04-17 US US14/689,387 patent/US9359301B2/en active Active
- 2015-07-27 HK HK15107144.3A patent/HK1206715A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
CL2015000891A1 (es) | Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras. | |
CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
CL2014000171A1 (es) | Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras. | |
CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
CL2016001895A1 (es) | Compuestos | |
CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
CL2008001994A1 (es) | Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras. | |
CL2015001318A1 (es) | Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras. | |
CL2013002053A1 (es) | Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct | |
CL2013002871A1 (es) | Compuestos derivados de 1,3-oxazinas con actividad inhibidora de bace 1 y bace 2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes tipo 2, trombosis arterial, cáncer, infarto al miocardio,lupus eritematoso, entre otros. | |
CL2015001537A1 (es) | Compuestos derivados de piridin-2-amidas agonistas cb2; proceso de sintesis; composicion farmaceutica; uso en el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras. | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
CL2013002424A1 (es) | Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras. | |
CL2015002202A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4. |